Radionuclide therapy with samarium oxabifore (153Sm) in patients with prostate cancer and bone metastases

Abstract

Objective: To study the clinical capacities of the radiopharmaceutical samarium oxabifore (¹⁵³Sm) in palliative therapy in prostate cancer patients with bone metastases and pain syndrome.

Subjects and methods: 53 patients with prostate cancer and multiple bone metastases and pain syndrome in whom ¹⁵³SM was intravenously injected once (n = 34), twice (n = 14), thrice (n = 5). The activities were used in the range of 1.0 to 1.5 mKu/kg body weight.

Results: The disposition of the radiopharmaceutical and its accumulation in the involved osseous tissue foci were studied. The agent was shown to be highly effective in palliative therapy for prostate cancer. There was a reduction in the intensity of patients in 40 (75.4%) patients for 3 months or more. Life quality improved (after the Karnovsky method). The side effects of radionuclide therapy were evaluated.